{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:34:47Z","timestamp":1787960087022,"version":"build-2784847793"},"reference-count":35,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":185,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We examined the effect of selenium vs placebo on remission rate and quality of life (QoL) in the Graves\u2019 selenium supplementation (GRASS) trial (ID: NCT01611896).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Double-blinded, placebo-controlled, multi-centre trial in individuals with newly diagnosed Graves\u2019 hyperthyroidism randomised to daily supplementation with 200 \u03bcg selenium or placebo tablets during 24\u201330 months, depending on the timing of antithyroid drug (ATD) withdrawal. The primary outcome was the proportion of participants with non-remission, defined as receiving ATD or remaining hyperthyroid (thyroid stimulating hormone &amp;lt;0.1 mIU\/L) during the last 12 months of the intervention period or referral to ablative therapy (radioactive iodine or surgery). QoL was serially assessed by the thyroid-related patient-reported outcome ThyPRO and compared with previously collected norm data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between Dec 7th 2012 and Dec 3rd 2018, 430 participants with Graves\u2019 hyperthyroidism were recruited. Non-remission was observed in 114 (53.3%) participants in the placebo group and 118 (54.6%) in the selenium group (OR = 1.0 (95% CI: 0.7\u20131.5); P = 0.98). There was no beneficial effect of selenium, as compared with placebo, on any ThyPRO scale. The participants\u2019 QoL at the end of the study was comparable to that of the general population sample. Thyrotropin receptor antibody levels were similar in the groups at the 18-month and end-of-study follow-up visits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In individuals with newly diagnosed Graves\u2019 hyperthyroidism, daily supplementation with selenium did not have any effects compared with placebo as add-on to standard antithyroid drugs. The GRASS trial findings do not support the use of selenium supplementation in Graves\u2019 hyperthyroidism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-25-0264","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:58:41Z","timestamp":1765544321000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":2,"title":["Selenium supplementation in individuals with newly diagnosed Graves\u2019 hyperthyroidism: a double-blind, multi-centre RCT"],"prefix":"10.1530","volume":"15","author":[{"given":"Per K","family":"Cramon","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian H","family":"Winther","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor B","family":"Boesen","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla B","family":"Larsen","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob B","family":"Bjorner","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma F","family":"Nordqvist","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L","family":"Forman","sequence":"additional","affiliation":[{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne B","family":"Juul","sequence":"additional","affiliation":[{"name":"6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1279-6627","authenticated-orcid":true,"given":"Pernille","family":"Bach-Mortensen","sequence":"additional","affiliation":[{"name":"6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Knudsen","sequence":"additional","affiliation":[{"name":"7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runa L","family":"Nols\u00f8e","sequence":"additional","affiliation":[{"name":"8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[{"name":"9"},{"name":"10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alin","family":"Andries","sequence":"additional","affiliation":[{"name":"11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe","family":"Gram","sequence":"additional","affiliation":[{"name":"11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9540-4950","authenticated-orcid":true,"given":"Birte","family":"Nygaard","sequence":"additional","affiliation":[{"name":"12"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Demircan","sequence":"additional","affiliation":[{"name":"13"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo S","family":"Chillon","sequence":"additional","affiliation":[{"name":"13"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Schomburg","sequence":"additional","affiliation":[{"name":"13"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Heged\u00fcs","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen J","family":"Bonnema","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9729-4767","authenticated-orcid":true,"given":"\u00c5se K","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torquil","family":"Watt","sequence":"additional","affiliation":[{"name":"14"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"2026070714005342900_bib1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"2026070714005342900_bib2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1089\/thy.2019.0634","article-title":"Effects of supplemental vitamin D on muscle performance and quality of life in graves\u2019 disease: a randomized clinical trial","volume":"30","author":"Grove-Laugesen","year":"2020","journal-title":"Thyroid"},{"key":"2026070714005342900_bib3","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1210\/clinem\/dgad538","article-title":"Outcomes of patients with graves disease 25 years after initiating antithyroid drug therapy","volume":"109","author":"Stokland","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714005342900_bib4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrendo.2011.174","article-title":"Selenium, selenoproteins and the thyroid gland: interactions in health and disease","volume":"8","author":"Schomburg","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"2026070714005342900_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41574-019-0311-6","article-title":"Selenium in thyroid disorders \u2013 essential knowledge for clinicians","volume":"16","author":"Winther","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"2026070714005342900_bib6","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1089\/thy.2016.0256","article-title":"Selenium supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: a systematic review and meta-analysis","volume":"26","author":"Wichman","year":"2016","journal-title":"Thyroid"},{"key":"2026070714005342900_bib7","article-title":"Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism","volume":"13","author":"Larsen","year":"2024","journal-title":"Eur Thyroid J"},{"key":"2026070714005342900_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/157340607780620662","article-title":"Serum selenium levels in patients with remission and relapse of graves\u2019 disease","volume":"3","author":"Wertenbruch","year":"2007","journal-title":"Med Chem"},{"key":"2026070714005342900_bib9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/cen.12185","article-title":"Serum selenium is low in newly diagnosed Graves\u2019 disease: a population-based study","volume":"79","author":"B\u00fclow","year":"2013","journal-title":"Clin Endocrinol"},{"key":"2026070714005342900_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3341\/kjo.2021.0146","article-title":"Serum selenium levels in patients with graves disease: associations with clinical activity and severity in a retrospective case-control study","volume":"36","author":"Kim","year":"2022","journal-title":"Korean J Ophthalmol"},{"key":"2026070714005342900_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000381768","article-title":"A prospective investigation of graves\u2019 disease and selenium: thyroid hormones, auto-antibodies and self-rated symptoms","volume":"4","author":"Calissendorff","year":"2015","journal-title":"Eur Thyroid J"},{"key":"2026070714005342900_bib12","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1055\/s-0042-110491","article-title":"Effect of selenium supplementation on recurrent hyperthyroidism caused by graves\u2019 disease: a prospective pilot study","volume":"48","author":"Wang","year":"2016","journal-title":"Horm Metab Res"},{"key":"2026070714005342900_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.886451","article-title":"Add-On effect of selenium and vitamin D combined supplementation in early control of graves\u2019 disease hyperthyroidism during methimazole treatment","volume":"13","author":"Gallo","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026070714005342900_bib14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40618-016-0559-9","article-title":"Effects of selenium on short-term control of hyperthyroidism due to Graves\u2019 disease treated with methimazole: results of a randomized clinical trial","volume":"40","author":"Leo","year":"2017","journal-title":"J Endocrinol Investig"},{"key":"2026070714005342900_bib15","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1210\/jc.2017-01736","article-title":"Double-blind, placebo-controlled, randomized trial of selenium in graves hyperthyroidism","volume":"102","author":"Kahaly","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714005342900_bib16","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves\u2019 orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med"},{"key":"2026070714005342900_bib17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jfo.2020.08.029","article-title":"Oral selenium improved the disease activity in patients with mild Graves\u2019 orbitopathy","volume":"44","author":"Almanza-Monterrubio","year":"2021","journal-title":"J Fr Ophtalmol"},{"key":"2026070714005342900_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/01676830.2024.2315566","article-title":"Selenium supplementation in inactive moderate to severe Graves\u2019 orbitopathy patients: a randomized controlled trial","volume":"43","author":"Potita","year":"2024","journal-title":"Orbit"},{"key":"2026070714005342900_bib19","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/s12020-023-03672-5","article-title":"Selenium in the treatment of mild-to-moderate Graves\u2019 orbitopathy: a 5-year prospective controlled cohort study","volume":"84","author":"Wang","year":"2024","journal-title":"Endocrine"},{"key":"2026070714005342900_bib20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaophthalmol.2024.6337","article-title":"Selenium vs control for graves ophthalmopathy in a selenium-sufficient area: a randomized clinical trial","volume":"143","author":"Ahn","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"2026070714005342900_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association Guideline for the management of graves\u2019 hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"key":"2026070714005342900_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000494837","article-title":"A 2018 European Thyroid Association Survey on the use of selenium supplementation in Graves\u2019 Hyperthyroidism and Graves\u2019 orbitopathy","volume":"8","author":"Negro","year":"2019","journal-title":"Eur Thyroid J"},{"key":"2026070714005342900_bib23","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1089\/thy.2022.0172","article-title":"A survey on the management of thyroid eye disease among American and European Thyroid Association members","volume":"32","author":"Brito","year":"2022","journal-title":"Thyroid"},{"key":"2026070714005342900_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1745-6215-14-119","article-title":"Selenium supplementation for patients with Graves\u2019 hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial","volume":"14","author":"Watt","year":"2013","journal-title":"Trials"},{"key":"2026070714005342900_bib25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1740774513517778","article-title":"Development and implementation of PROgmatic: a clinical trial management system for pragmatic multi-centre trials, optimised for electronic data capture and patient-reported outcomes","volume":"11","author":"Cramon","year":"2014","journal-title":"Clin Trials"},{"key":"2026070714005342900_bib26","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1089\/thy.2015.0209","article-title":"Development of a short version of the thyroid-related patient-reported outcome ThyPRO","volume":"25","author":"Watt","year":"2015","journal-title":"Thyroid"},{"key":"2026070714005342900_bib27","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1210\/jc.2014-1322","article-title":"The thyroid-related quality of life measure ThyPRO has good responsiveness and ability to detect relevant treatment effects","volume":"99","author":"Watt","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714005342900_bib28","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/thy.2014.0433","article-title":"Quality of life in patients with benign nontoxic goiter: impact of disease and treatment response, and comparison with the general population","volume":"25","author":"Cramon","year":"2015","journal-title":"Thyroid"},{"key":"2026070714005342900_bib29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Roy Stat Soc B"},{"key":"2026070714005342900_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jtemb.2009.03.009","article-title":"Serum selenium and selenoprotein P status in adult Danes \u2013 8-year followup","volume":"23","author":"Rasmussen","year":"2009","journal-title":"J Trace Elem Med Biol"},{"key":"2026070714005342900_bib31","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1530\/EC-21-0026","article-title":"Determining minimal important change for the thyroid-related quality of life questionnaire ThyPRO","volume":"10","author":"Nordqvist","year":"2021","journal-title":"Endocr Connect"},{"key":"2026070714005342900_bib32","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1210\/jc.2015-2222","article-title":"Low population selenium status is associated with increased prevalence of thyroid disease","volume":"100","author":"Wu","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714005342900_bib33","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1089\/thy.2018.0315","article-title":"Impaired quality of life after radioiodine therapy compared to antithyroid drugs or surgical treatment for graves\u2019 hyperthyroidism: a long-term follow-up with the thyroid-related patient-reported outcome questionnaire and 36-item short form health status survey","volume":"29","author":"T\u00f6rring","year":"2019","journal-title":"Thyroid"},{"key":"2026070714005342900_bib34","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41574-024-01022-7","article-title":"Medically not yet explained symptoms in hypothyroidism","volume":"20","author":"Heged\u00fcs","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2026070714005342900_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1000682","article-title":"Implementation of thyroid-related patient-reported outcomes in routine clinical practice","volume":"13","author":"Cramon","year":"2022","journal-title":"Front Endocrinol"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/15\/1\/ETJ-25-0264.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/15\/1\/ETJ-25-0264.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0264\/508646\/etj-25-0264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0264\/508646\/etj-25-0264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:01:03Z","timestamp":1783447263000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/15\/1\/ETJ250264\/75638\/Selenium-supplementation-in-individuals-with-newly"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-25-0264","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"article-number":"ETJ250264"}}